SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1657)1/27/2006 7:38:31 AM
From: sammaster  Read Replies (1) | Respond to of 1826
 
"A sponsor of a 505(b)(2) application for a change to a listed drug product must also file a patent certification and exclusivity statement and may not market the approved product until patent/exclusivity attached to that drug product has expired or the patent has been successfully challenged"

so they will have to do the trial, then fight aloxi patent, and then only have 3 years exclucivity?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News